Needham Reiterates Buy on Selecta Biosciences, Maintains $5 Price Target
Needham analyst Gil Blum reiterates Selecta Biosciences (NASDAQ:SELB) with a Buy and maintains $5 price target.
Earnings Scheduled For March 2, 2023
Companies Reporting Before The Bell
• argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.
5 Value Stocks In The Healthcare Sector
The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the…
Analyst Says Selecta Biosciences’ Gout Candidate Can Potentially Raise The Bar On Several Fronts
Canaccord Genuity has increased the price target for Selecta Biosciences Inc (NASDAQ:SELB) from $9 to $10 while maintaining the Buy rating ahead of…
A Look Into Healthcare Sector Value Stocks
Understanding Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies…
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Why Rogers Shares Are Trading Sharply Lower; Here Are 33 Stocks Moving Premarket
Gainers
Avinger, Inc. (NASDAQ: AVGR) rose 32% to $1.36 in pre-market trading. Avinger is expected to release its financial results for the third quarter on Wednesday, November 9, 2022.
Match Group, Super Micro Computer And Some Other Big Stocks Moving Higher In Today’s Pre-Market Session
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Selecta Biosciences’s Return On Capital Employed Overview
Pulled from Benzinga Pro data, Selecta Biosciences (NASDAQ:SELB) showed a loss in earnings since Q1, totaling $8.60 million. Sales, on the other hand, increased by 15.51% to $39.27 million during Q2.
